Gut-Liver Interactions: From IBD to · PDF fileSerum levels of lectin complement pathway...

Program

P 20

1e 1

-2/2

016

/550

Stü

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49 (0) 761/15 14-125Telefax: +49 (0) 761/15 14-359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

Symposium 201

Gut-Liver Interactions: From IBD to NASH

March 11 – 12, 2016Congress Innsbruck Innsbruck, Austria

CME credits 11

Awarded with

116419_Falk_Innsbruck_Symp_201_Prog_UG.indd 1 01.02.16 16:16

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

List of Speakers, Moderators and Scientific Organizers . . . . . . . . . . . . . . . . . . . . . . . . 16

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

11 credit hours (CME) have been awarded for the Symposium 201 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG) .

116419_Falk_Innsbruck_Symp_201_Prog_Inhalt.indd 3 07.03.16 10:56

4

Preface

Various hot topics of the last years such as innate immunity or the microbiota have increasingly boosted the sense to link again gut and liver diseases and consider common mechanisms and relationships . These common views are the incentives behind our goals for the Symposium 201 in Innsbruck, which intends to stimulate attendants to discuss gut-liver interactions from pathophysiology towards therapeutic approaches . We have been lucky in attracting excellent and well renowned speakers from both the gastroenterology and hepatology field . The selection of topics was based on the assumption to discuss fields where such interactions are obvious and highly relevant as in non-alcoholic fatty liver diseases (NAFLD) or inflammatory bowel diseases (IBD) . An important feature of this Symposium is the role of innate immunity and the gut microbiota in these interactions and these aspects will be especially highlighted . Colleagues with a primarily clinical focus will receive a thorough update in topics such as IBD, NAFLD, alcoholic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis .

We, the organizers of this meeting, extend our grateful thanks to Mrs . Ursula Falk and the Falk Foundation e .V . for making it possible to organize this highly respected type of meeting . It is of course also our hope that besides listening to great talks, the Symposium 201 will allow people to meet friends, discuss hot topics and will also bring home to you some of the excitements of our wonderful city .

On behalf of the scientific organizing committee,

Prof . Dr . Herbert Tilg, Innsbruck


55

Symposium 201


Congress InnsbruckInnsbruck, Austria

Registration:Thursday, March 10, 201616 .00 – 21 .00 hat the congress offi ce

Scientifi c Organization:A . Kaser, Cambridge (Great Britain)M . P . Manns, Hannover (Germany)G . Szabo, Worcester (USA)H . Tilg, Innsbruck (Austria)M . Trauner, Vienna (Austria)

Congress Venue:Congress Innsbruck Rennweg 3 6020 InnsbruckAustria

Information:Prof . Dr . Herbert TilgUniversitätsklinik InnsbruckInnere Medizin IAnichstr . 356020 InnsbruckAustriaTelephone: +43 (0) 50 504 23539Telefax: +43 (0) 50 504 23538E-Mail: herbert .tilg@i-med .ac .at

Offi cial Language:English

Posters:For details see page 10 .


6

Friday, March 11, 2016

9.00 Welcome H . Tilg, Innsbruck

H . Fritsch, Innsbruck

Session I NAFLD

Chair: H . Tilg, Innsbruck; M . Trauner, Vienna

9.10 Pathophysiology of NAFLD G . Marchesini, Bologna

9.30 Extrahepatic diseases and NAFLD: The triangular C . D . Byrne, relationship between NAFLD, type 2-diabetes and Southampton dysbiosis

9.50 How to diagnose NAFLD C . P . Day, Newcastle-Upon-Tyne

10.10 Treatment of NAFLD J .-F . Dufour, Bern

10.30 Coffee break with poster session

Session II Alcoholic liver disease

Chair: G . Szabo, Worcester; W . Vogel, Innsbruck

11.00 Pathophysiological aspects of alcoholic steatohepatitis R . Jalan, London

11.20 Co-morbidities in ASH R . Bataller, Chapel Hill

11.40 Treatment of alcoholic hepatitis P . Mathurin, Lille

12.00 ASH and NASH: A relevant association C . Hellerbrand, Regensburg

12.20 Lunch break with poster session


7

Friday, March 11, 2016 Session III

PBC/PSC Chair: M . P . Manns, Hannover; M . Trauner, Vienna

14.20 Genetics of PSC J . R . Hov, Oslo

14.40 The mucosal immunity of PBC and PSC P . Trivedi, Birmingham

15.00 Cancer risk and PSC T . Lankisch, Hannover

15.20 Therapy of PBC/PSC U . Beuers, Amsterdam


Session IV Gut-liver interactions: From microbiota to immunity

Chair: A . Kaser, Cambridge; H . Zoller, Innsbruck

16.10 State-of-the-Art: K . Kristiansen, Gut microbiome analyses for diagnosis and targeted Copenhagen treatment

16.30 Microbiota and their role in gut-liver interactions S . C . Bischoff, Stuttgart

16.50 Iron and innate immunity G . Weiss, Innsbruck

17.10 State-of-the-Art: C . A . Dinarello, Anti-IL-1 strategies in human diseases – a success story Denver


8

Saturday, March 12, 2016 Session V

Evolving IBD pathogenesis Chair: W . Petritsch, Graz; G . Rogler, Zurich

9.00 Multiomics approach – from genetics to metabolomics S . Schreiber, Kiel

9.20 Immunopathogenesis of IBD M . F . Neurath, Erlangen

9.40 The search for causative environmental factors in IBD G . Rogler, Zurich

10.00 Emerging therapies for IBD A . R . Moschen, Innsbruck


Session VI IBD – diagnosis and therapy

Chair: P . Knoflach, Wels; H . Vogelsang, Vienna

10.50 Role of MRI in IBD patient management J . Panés, Barcelona

11.10 Aminosalicylates and corticosteroids in IBD A . Dignass, Frankfurt

11.30 Are immunosuppressants becoming obsolete? B . Siegmund, Berlin

11.50 Anti-TNF and anti-integrin therapies: G . D’Haens, Still second line? Amsterdam

12.10 Presentation of poster awards M . P . Manns, Hannover

12.20 Lunch break with poster session


9

Saturday, March 12, 2016 Session VII

Precision medicine in IBD Chair: G . Novacek, Vienna; G . R . van den Brink, Amsterdam

13.30 Proper use of IBD drugs in pregnancy C . J . van der Woude, Rotterdam

13.50 Early surgery for ileocoecal Crohn’s disease? W . A . Bemelman, Amsterdam

14.10 Personalisation in the treatment of IBD reveals a K . Smith, distinct biology of clinical outcome in immune- Cambridge mediated disease?

14.30 Where next? – Game changers on the horizon B . G . Feagan, London, ON


Session VIII IBD – environmental factors

Chair: A . R . Moschen, Innsbruck; H . Tilg, Innsbruck

15.20 Microbiota and IBD: Key player? P . Rosenstiel, Kiel

15.40 Any future for fecal transplant as treatment C . Högenauer, strategy for IBD? Graz

16.00 Closing remarks


10

Poster SessionPosters will be exhibited on March 11-12, 2016 at Congress Innsbruck . The authors will be in attendance during coffee and lunch breaks on both days .

1 . Comorbidities in alcoholic liver cirrhosis A . Adamenka (Minsk, BY)

2 . Crohn’s and ulcerative colitis questionnaire-8 (CUCQ-8), a valid and quick Quality of Life measure in IBD L . Alrubaiy, P . Dodds, H .A . Hutchings, J .G . Williams (Swansea, GB)

3 . Development and validation of a new disease severity index: The inflammatory bowel disease index (IBDex©) L . Alrubaiy, P . Dodds, H .A . Hutchings, I .T . Russell, A . Watkins, J .G . Williams (Swansea, GB)

4 . Dendritic cells, TGF-β1 and insulin-like growth factor II mRNA binding protein 3 – „Heroes or villains” in IBD pathology Y . Ananiev, K . Ivanova, M . Penkova, M . Gulubova (Stara Zagora, BG)

5 . The peculiarities of colonic microbiota in patients with NSAID-associated liver injury A . Antonenko, T . Beregova, A . Svintsitsky (Kiev, UA)

6 . De-novo IBD as one of significant risk factors for PSC recurrence after liver transplantation L . Bajer, E . Sticova, P . Macinga, R . Janousek, P . Trunecka, J . Spicak, P . Drastich (Prague, CZ)

7 . PSC patients have different microbiota composition as compared to UC L . Bajer, M . Kostovcik, M . Kverka, P . Macinga, J . Brezina, J . Spicak, P . Drastich (Prague, CZ)

8 . Cardiovascular risk factors in young patients with inflammatory bowel disease associating non-alcoholic steatohepatitis M .C . Bezna, C . Deliu, M . Bezna, C . Pitis (Craiova, RO)

9 . The importance of oxidative stress assessment in patients with inflammatory bowel disease associating non-alcoholic steatohepatitis M . Bezna, C . Deliu, M .C . Bezna, C . Pitis, M . Balasoiu (Craiova, RO)

10 . Circulating bone marrow derived CD45-/CD34+/CD133+/VEGF+ endothelial progenitor cells in adults with Crohn’s disease D . Boltin, Z . Kamenetsky, T .T . Perets, D . Luria, Y . Snir, B . Sapoznikov, R . Dickman, Y . Niv (Petah-Tikva, Tel Aviv, IL)

11 . Successful pregnancies with thiopurine-allopurinol co-therapy for inflammatory bowel disease C . Bull, M . Sheikh, C . Nelson-Piercy, J . Stenner, J . Duley, T . Florin, A . Ansari (Redhill, Surrey, London, GB; Brisbane, AU)


11

12 . Can fecal transplant represent a solution for inflammatory bowel disease and clostridium difficile infection? A . Constantin, M . Ilie, G . Constantinescu, D . Tabacelia (Bucharest, RO)

13 . Isolated tongue tremor in patient with liver cirrhosis H . Demirci, K . Ozturk, M . Korkmaz, M . Kantarcioglu, A . Uygun, S . Bagci (Ankara, TR)

14 . IBD phenotypes differ in gut mycobiota composition P . Drastich, L . Bajer, K . Klimesova, M . Kostovcik, M . Kverka, P . Macinga, J . Brezina, J . Spicak (Prague, CZ)

15 . Serum levels of lectin complement pathway molecules do not primarily determine the risk of bacterial infections in patients with cirrhosis I . Foldi, D . Tornai, T . Tornai, Z . Vitalis, I . Tornai, T . Dinya, P . Antal-Szalmas, M . Papp (Debrecen, HU)

16 . The effect of the therapy with UDCA and budesonide on histological evolution of the primary biliary cirrhosis in patients with incomplete response to UDCA monotherapy A . Genunche-Dumitrescu, M . Badea, D . Badea, P . Mitrut, D . Neagoe, A . Badea, C . Deliu (Craiova, RO)

17 . Probiotics in association with UDCA in the treatment of the nonalcoholic steato-hepatitis in obese patients A . Genunche-Dumitrescu, D . Badea, M . Badea, P . Mitrut, A . Badea, C . Deliu, O . Diaconu (Craiova, RO)

18 . Rifaximin reduces the number, but not length, of hospital admissions in patients with refractory hepatic encephalopathy S . Ghuman, C . Ridley, M .A . Czajkowski, A .D . Yeoman (Newport, GB)

19 . The role of prophylactic treatment with A . muciniphila in the acute alcoholic liver disease C . Grander, V . Wieser, R .R . Gerner, F . Grabherr, T .E . Adolph, L . Lichtmannegger, A . Pfister, B . Enrich, A .R . Moschen, H . Tilg (Innsbruck, AT)

20 . Evaluation of Ki-67 and PCNA expression in Crohn’s disease K . Guzinska-Ustymowicz, A . Pryczynicz, K . Jakubowska, M . Ustymowicz, J . Sieczka, M . Maciorkowska, E . Maciorkowska (Bialystok, PL)

21 . The influence of anti-TNF-α agents on serum lipid profile and atherogenic index in patients with inflammatory bowel diseases C . Kalkan, F . Karakaya, Z .B . Genctürk, M . Törüner, H . Cetinkaya, I . Soykan (Ankara, TR)

22 . Long-term UDCA therapy in the patients with primary sclerosing cholangitis A . Karadzova, M . Miloshevski, V . Serafimoski, V . Caloska Ivanova, D . Janevska, E . Nikolovska, A . Volkanovska (Skopje, MK)

23 . Prevalence of non-alcoholic fatty liver disease in inflammatory bowel disease patients treated with anti-TNF D .G . Karamanolis, N . Viazis, J . Anastasiou, L . Varytimiadis, M . Galanopoulos, K . Katopodi, T . Tsigaridas, E . Antypa (Athens, GR)


12

24 . Evaluation of the presence of A-allele HERC2 (rs916977) and the presence of perianal fistula in Egyptian Crohn’s disease M .H . Khalaf, O .E . Salem, T .M . Thabet, D . Elkaffash, W . Mekky, S . Elkady, M . Abdelhafiez (Alexandria, EG)

25 . Morphofunctional parameters of the gallbladder in patients with non-alcoholic fatty liver disease (NAFLD) S .I . Konenko, V .B . Yagmur, N .P . Dementiy, N .V . Nedzvetskaya (Dnipropetrovsk, UA)

26 . Nonalcoholic fatty liver disease detected by transient elastography in the patients with inflammatory bowel disease – A pilot study I . Krznaric-Zrnic, I . Mikolasevic, B . Mijandrusic-Sincic, N . Franjic, D . Stimac, L . Orlic, S . Milic (Rijeka, HR)

27 . Most liver related deaths in India are caused by alcohol: An audit of liver mortality from tertiary care center in North India A . Kumar, V . Gupta, A . Arora (New Delhi, IN)

28 . Intestinal microvascular density (MVD) in active inflammatory bowel disease (IBD) in colonoscopic biopsies from adult patients – pathologic angiogenesis closely associated with progression of the disease J .M . Lotowska, M .E . Sobaniec-Lotowska, U . Daniluk, B . Kosztyla-Hojna, J . Reszec (Bialystok, PL)

29 . Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn’s disease P .W .J . Maljaars (Leiden, NL)

30 . Peculiarities of treatment the patients with nonalcoholic steatohepatitis combined with diabetes mellitus of the type 2 at the stage of sanatorium-resort rehabilitation G . Maslova, Y . Mandyka, I .N . Skrypnyk (Poltava, UA)

31 . Rosuvastatin or ursodeoxycholic acid in the treatment of the non-alcoholic stea-tohepatitis in patients with acute myocardial infarction and metabolic syndrome? G . Maslova, T . Dubrovinska, I .N . Skrypnyk (Poltava, UA)

32 . Ursodeoxycholic acid in the treatment of alcoholic liver disease E . Nikolovska, V . Caloska Ivanova, M . Miloshevski, R . Popova Jovanovska, M . Trajkovska, B . Todorovska, D . Janevska, A . Karadzova (Skopje, MK)

33 . Target-specific anti-pancreatic antibodies are frequent in patients with primary sclerosing cholangitis and associated with poor disease outcome M . Papp, T . Tornai, G . Kovacs, Z . Vitalis, I . Tornai, K . Fechner, D . Roggenbuck, D . Tornai, G .L . Norman, Z . Shums, G . Veres, P . Orosz, B . Lombay, J . Gervain, G . Par, A . Par, P .L . Lakatos, F . Szalay, P . Antal-Szalmas (Debrecen, HU; Lübeck, Senftenberg, DE; San Diego, US; Budapest, Miskolc, Szekesfehervar, Pecs, HU)

34 . The diversity of the alcoholic steatohepatitis associated diseases – A single-cause matter O . Petrascu, C . Cipaian, A . Boicean (Sibiu, RO)


13

35 . Correlation of anemia prevalence in hospitalized patents with inflammatory bowel disease with disease activity and localization A . Pilav, D . Prohic, R . Mesihovic, N . Vanis (Sarajevo, BA)

36 . Association of PPAR-Gamma2 Pro12Ala and ACE I/D genes polymorphisms with metabolic and immune disorders in obese patients with NAFLD and hypertension O .M . Plehutsa, R .I . Sydorchuk, T .M . Boychuk, L .P . Sydorchuk, A .R . Sydorchuk, I .I . Sydorchuk, Y . Yarynych (Chernivtsi, UA)

37 . A possible impact of Helicobacter pylori infection on non-alcoholic fatty liver disease S .A . Polyzos, D . Chatzopoulos, E . Stefanidis, A . Papatheodorou, K . Patsiaoura, E . Katsiki, E . Zafeiriadou, C . Zavos, K . Anastasiadou, E . Terpos, J . Kountouras (Thessaloniki, Athens, GR)

38 . Comparison of MELD and child-pugh score short time prognostic significance in patients with decompensated liver cirrhosis: A Bosnian experience D . Prohic, A . Pilav, R . Mesihovic, N . Vanis (Sarajevo, BA)

39 . Proliferating cell nuclear antigen PCNA is associated with dysplasia in ulcerative colitis A . Pryczynicz, M . Ustymowicz, K . Jakubowska, E . Maciorkowska, M . Maciorkowska, J . Sieczka, K . Guzinska-Ustymowicz (Bialystok, PL)

40 . Systematic review of the clinical disease severity indices for inflammatory bowel disease I . Rikaby, L . Alrubaiy, M . Sageer, H .A . Hutchings, J .G . Williams (Cardiff, Swansea, GB; Massachusetts, US)

41 . Can the inflammatory bowel disease biologics registry lead to improved quality of care? I . Rikaby, L . Alrubaiy, H .A . Hutchings, J .G . Williams (Cardiff, Swansea, GB)

42 . Clinical implications of alpha-1-antitrypsin deficiency causing iron overload and cirrhosis B . Schäfer, D . Haschka, R . Hilbe, A . Finkenstedt, I . Tancevski, I . Theurl, W . Vogel, G . Weiss, H . Zoller (Innsbruck, AT)

43 . Treatment of spontaneous bacterial peritonitis in a local hospital S . Shwana (Merthyr Tydfil, GB)

44 . A case of Mirizzi’s syndrome S . Shwana (Merthyr Tydfil, GB)

45 . A case of amoebic liver abscess S . Shwana (Merthyr Tydfil, GB)

46 . Maintenance of antithrombotic therapy post endoscopy for acute upper gastro-intestinal bleeding is associated with improved clinical outcomes K . Siau, J . Hannah, M . Widlak, T . Iqbal, N . Bhala (Birmingham, GB)

47 . Bacterial infections in alcoholic liver cirrhosis N . Silivontchik, D . Haurylenka (Minsk, Gomel, BY)


14

48 . Especially the accumulation of fat in patients with non-alcoholic fatty liver disease N . Silivontchik, D . Adinets, N . Vasilieva, I . Kachar (Minsk, Grodno, BY)

49 . Intestinal dysbiosis as a leading factor in dyslipidemia progression in patients with nonalcoholic steatohepatitis I .N . Skrypnyk, G . Maslova, E . Ohanesian (Poltava, UA)

50 . The role of nonalcoholic fatty liver disease in the progression of atherogenic dyslipidemia in patients with ischemic heart disease I .N . Skrypnyk, G . Maslova, O .V . Hapon (Poltava, UA)

51 . Mucosal angiogenesis in active inflammatory bowel disease (IBD): Immunohisto-chemical study of CD31 and CD34 expression in colonoscopic biopsies . The first report in pediatric patients M .E . Sobaniec-Lotowska, J .M . Lotowska, U . Daniluk, S .B . Lotowska, D .M . Lebensztejn (Bialystok, PL)

52 . Polimorphisms of IL-4 (C-590T), TNF-α (G-308A), PRSS1 (R122H) and CFTR (delF508C) genes, NAFLD, ASH, pancreatitis and cholestasis L .P . Sydorchuk, S .I . Ivashchuk, R .I . Sydorchuk, Y .M . Yarynych, I .I . Sydorchuk, O .M . Plehutsa, A .R . Sydorchuk (Chernivtsi, UA)

53 . Intestinal dysbiosis, hemodynamic peculiarities of mesenteric vessels, non-alcoholic fatty liver disease and genetic polymorphisms of ACE (I/D) and AGTR1 (A1166C) genes R .I . Sydorchuk, L .P . Sydorchuk, O .V . Kushnir, O .M . Iftoda, A .R . Sydorchuk, I .I . Sydorchuk, O .M . Plehutsa (Chernivtsi, UA)

54 . Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis T . Tornai, G . Kovacs, Z . Vitalis, I . Tornai, K . Fechner, D . Roggenbuck, D . Tornai, G .L . Norman, Z . Shums, G . Veres, P . Orosz, B . Lombay, J . Gervain, G . Par, A . Par, P .L . Lakatos, F . Szalay, P . Antal-Szalmas, M . Papp (Debrecen, HU; Lübeck, Senftenberg, DE; San Diego, US; Budapest, Miskolc, Szekesfehervar, Pecs, HU)

55 . Simultaneous presence of IL-17A-producing T cells and FoxP3+ T cells in IBD mucosa T . Velikova, I . Karakolev, Z . Spassova, E . Ivanova-Todorova, K . Toumangelova-Yuzeir, D . Kyurkchiev, I . Altankova, S . Stanilova (Sofia, Stara Zagora, BG)

56 . Serum ferritin level is associated with diseases severity and markers of bacterial translocation but not with long-term disease course in cirrhosis Z . Vitalis, T . Tornai, I . Tornai, D . Tornai, G .L . Norman, Z . Shums, P . Antal-Szalmas, A . Tordai, M . Papp (Debrecen, HU; San Diego, US; Budapest, HU)

57 . Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease V . Wieser, P . Tymoszuk, T .E . Adolph, C . Grander, F . Grabherr, B . Enrich, A . Pfi-ster, L . Lichtmannegger, R . Gerner, M . Drach, P . Moser, H . Zoller, G . Weiss, A .R . Moschen, I . Theurl, H . Tilg (Innsbruck, AT; Zurich, CH)


15

58 . Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors V . Wieser, T .E . Adolph, B . Enrich, A . Kuliopulos, A . Kaser, H . Tilg, N .C . Kaneider (Innsbruck, AT; Massachusetts, US; Cambridge, GB)

59 . Restoration of low adipose PNPLA3 concentrations after bariatric surgery V . Wieser, T .E . Adolph, V . Thöni, A .R . Moschen, H . Tilg (Innsbruck, AT)

60 . Analysis of CCR9 and β7 in patients with primary sclerosing cholangitis and ulcerative colitis K .D . Williamson, B . van Wilgenburg, C .B . Willberg, R .W . Chapman, P . Klenerman, S . Keshav (Oxford, GB)

61 . Radiology in IBD, for medical trainees G . Woodfield, B .L . Phillips, A . Chavda (London, GB)

62 . The Doppler flow study for the assessment of the alcoholic liver lesion G . Zabielski, M . Broncel, A . Bala, J . Zabielska (Lodz, PL)

63 . Recurrent primary sclerosing cholangitis after liver transplantation: Case report P . Zalizko, V . Mokricka, L . Erne, A . Pukitis, J . Pokrotnieks (Riga, LV)

64 . Multifactorial risk prediction model for refractory Crohn’s disease patients K . Zupancic, K . Skok, V . Kalacun, K . Repnik, P . Skok, U . Potocnik (Maribor, SI)


16

List of Speakers, Moderators and Scientific Organizers

Ramon Bataller, M.D., Ph.D.Dept . of Gastroenterologyand HepatologySchool of MedicineUniversity of North Carolina101 Manning DriveChapel Hill, NC 27514USAramon_bataller@med .unc .edu

Dr. Willem A. BemelmanDepartment of SurgeryTytgat Institute for Liver & Intestinal ResearchUniversity of AmsterdamMeibergdreef 91105 AZ AmsterdamThe Netherlandsw .a .bemelman@amc .uva .nl

Prof. Dr. Ulrich BeuersDepartment of Gastroenterologyand Hepatology, G4-216Tytgat Institute for Liver & Intestinal ResearchUniversity of AmsterdamMeibergdreef 91105 AZ AmsterdamThe Netherlandsu .h .beuers@amc .uva .nl

Prof. Dr. Stephan C. BischoffInstitut für ErnährungsmedizinUniversität HohenheimFruwirthstr . 1270599 StuttgartGermanybischoff .stephan@uni-hohenheim .de

Prof. Dr. Christopher D. Byrne Professor of Endocrinology & MetabolismHuman Development and Health Academic Unit Faculty of Medicine The Institute of Developmental SciencesMP887University of SouthamptonSouthampton General HospitalSouthampton SO16 6YDGreat Britaincdtb@soton .ac .uk

Prof. Dr. Christopher P. DayFaculty of Medical SciencesNewcastle UniversityThe Medical SchoolWilliam Leech BuildingFramlington PlaceNewcastle-Upon-Tyne NE2 4HHGreat Britainchris .day@ncl .ac .uk

Prof. Dr. Geert D‘HaensAcademic Medical CenterAfdeling MDL C2-112Meibergdreef 91105 AZ AmsterdamThe Netherlandsg .dhaens@amc .uva .nl

Prof. Dr. Axel DignassMedizinische Klinik IAGAPLESIONMarkus KrankenhausWilhelm-Epstein-Str . 460431 FrankfurtGermanyaxel .dignass@fdk .info

Charles A. Dinarello, M.D.Professor of MedicineUniversity of Colorado Denver12700 East 19th Ave ., B168Aurora, CO 80045USAcdinare333@aol .com


17

Prof. Dr. Jean-Francois DufourDirector UVCM HepatologyUniversity of BernInselspital3010 BernSwitzerlandjf .dufour@ikp .unibe .ch

Dr. Brian G. FeaganWestern UniversityRobarts Research InstituteRobarts Clinical Trials100 Dundas Street, Suite 200London, ON N6A 5B6Canadabrian .feagan@robartsinc .com

Univ.-Prof. Dr. Helga FritschMedizinische Universität InnsbruckChristoph-Probst-Platz 1 Innrain 526020 InnsbruckAustriarektorat@i-med .ac .at

Prof. Dr. Claus HellerbrandKlinik für Innere Medizin IUniversitätsklinikum RegensburgFranz-Josef-Strauß-Allee 1193053 RegensburgGermanyclaus .hellerbrand@klinik .uni-regensburg .de

Prof. Dr. Christoph HögenauerKlinische Abteilung für Gastroenterologie und HepatologieUniversitätsklinik für Innere Medizin GrazMedizinische Universität GrazAuenbruggerplatz 158036 GrazAustriachristoph .hoegenauer@medunigraz .at

Dr. Johannes R. HovOslo UniversityHospital RiskohospitaletSognsvannveien 200027 OsloNorwayj .e .r .hov@medisin .uio .no

Prof. Dr. Rajiv JalanProfessor of HepatologyLiver Failure GroupInst . for Liver and Digestive HealthUCL Medical SchoolRowland Hill StreetLondon NW3 2PFGreat Britainr .jalan@ucl .ac .uk

Prof. Dr. Arthur KaserDivision of Gastroenterology& HepatologyUniversity of CambridgeAddenbrooke‘s HospitalHills RoadCambridge CB2 0QQGreat Britainak729@cam .ac .uk

Prof. Dr. Peter KnoflachInnere Medizin IKlinikum WelsGrieskirchnerstr . 424600 WelsAustriapeter .knoflach@klinikum-wegr .at

Prof. Dr. Karsten KristiansenLaboratory of Genomics and Molecular BiomedicineAugust Krogh BuildingDepartment of BiologyUniversity of CopenhagenUniversitetsparken 132100 CopenhagenDenmarkkk@bio .ku .dk

Prof. Dr. Tim LankischKlinik für Gastroenterologie,Hepatologie und EndokrinologieMedizinische Hochschule HannoverCarl-Neuberg-Str . 130625 HannoverGermanylankisch .tim@mh-hannover .de


18

Prof. Dr. Michael P. MannsKlinik für Gastroenterologie,Hepatologie und EndokrinologieMedizinische Hochschule HannoverCarl-Neuberg-Str . 130625 HannoverGermanymanns .michael@mh-hannover .de

Prof. Dr. Giulio MarchesiniIstituto di Patologia Medica IUniversità di BolognaPoliclinico S . OrsolaVia Massarenti 940138 BolognaItalygiulio .marchesini@unibo .it

Dr. Philippe MathurinUnit MADHôpital Claude HuriezRue Michel Polonovski59037 LilleFrancephilippe .mathurin@chru-lille .fr

Prof. Dr. Alexander R. MoschenMedizinische Universität InnsbruckUniversitätsklinik für Innere Medizin IAnichstr . 356020 InnsbruckAustriaalexander .moschen@i-med .ac .at

Prof. Dr. Markus F. NeurathMedizinische Klinik IUniversitätsklinikumErlangen-NürnbergUlmenweg 1891054 ErlangenGermanymarkus .neurath@uk-erlangen .de

Prof. Dr. Gottfried NovacekGastroenterologie/HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 WienAustriagottfried .novacek@meduniwien .ac .at

Prof. Dr. Julián PanésInflammatory Bowel Disease UnitHospital Clinico y ProvincialUniversidad de Barcelonac/ Villarroel no . 17008036 BarcelonaSpainjpanes@clinic .ub .es

Prof. Dr. Wolfgang PetritschKlinische Abteilung für Gastroenterologie und HepatologieUniv .- Klinik f . Innere Medizin GrazAubenbruggerplatz 158036 GrazAustriawolfgang .petritsch@medunigraz .at

Prof. Dr. Dr. Gerhard RoglerKlinik für Gastroenterologie& HepatologieUniversitätsspital ZürichRämistrasse 1008091 ZürichSwitzerlandgerhard .rogler@usz .ch

Prof. Dr. Philip RosenstielAllgemeine Innere Medizin undKlinische MolekularbiologieChristian-Albrechts-UniversitätCampus KielSchittenhelmstrasse 1224105 KielGermanyp .rosenstiel@mucosa .de

Prof. Dr. Stefan SchreiberInnere Medizin IUniversitätsklinikumSchleswig-Holstein, Campus KielArnold-Heller-Straße 3 (Haus 6)24105 KielGermanys .schreiber@mucosa .de


19

Prof. Dr. Britta SiegmundGastroenterologieCharité UniversitätsmedizinCampus Benjamin Franklin (CBF)Hindenburgdamm 3012203 BerlinGermanybritta .siegmund@charite .de

Prof. Dr. Ken SmithDepartment of Medicine University of CambridgeCambridge CB2 0XY Great Britainhodmed@medschl .cam .ac .uk

Gyongyi Szabo, M.D., Ph.D.Professor of MedicineDepartment of MedicineMedical SchoolUniversity of Massachusetts55 Lake Avenue NorthWorcester, MA 01655USAgyongyi .szabo@umassmed .edu

Prof. Dr. Herbert TilgInnere Medizin IUniversitätsklinik InnsbruckAnichstr . 356020 InnsbruckAustriaherbert .tilg@i-med .ac .at

Prof. Dr. Michael TraunerKlinische Abteilung fürGastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 WienAustriamichael .trauner@meduniwien .ac .at

Dr. Palak TrivediHepatology and GastroenterologyNIHR Centre for Liver ResearchUniversity of Birmingham5th Floor IBR Building, Wolfson DriveBirmingham, B32 3HRGreat Britainp .j .trivedi@bham .ac .uk

Dr. Gijs R. van den BrinkDepartment of Gastroenterology& HepatologyAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamThe Netherlandsg .r .vandenbrink@amc .uva .nl

Prof. Dr. C. Janneke van der WoudeAfd . GastroenterologieErasmus Medical Centers-Gravendijkwal 2303015 CE RotterdamThe Netherlandsc .vanderwoude@erasmusmc .nl

Prof. Dr. Wolfgang VogelInnere Abteilung IIUniversitätsklinik InnsbruckAnichstr . 356020 InnsbruckAustriawolfgang .vogel@i-med .ac .at

Prof. Dr. Harald VogelsangInnere Abteilung IVGastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 WienAustriaharald .vogelsang@meduniwien .ac .at

Prof. Dr. Günter WeissInnere Abteilung IVUniverstitätsklinik InnsbruckAnichstr . 356020 InnsbruckAustriaguenter .weiss@i-med .ac .at

Dr. Heinz ZollerGastroenterologie/HepatologieUniversitätsklinik InnsbruckAnichstr . 356020 InnsbruckAustriaheinz .zoller@i-med .ac .at


20

Congress OfficeDuring the Symposium 201

Congress Innsbruck Telephone: +49 (0)175/7795327Rennweg 3 6020 InnsbruckAustria

Opening Hours:Thursday, March 10, 2016 16 .00 – 21 .00 hFriday, March 11, 2016 8 .00 – 17 .30 hSaturday, March 12, 2016 8 .30 – 16 .00 h

Admission to Scientific EventsFor admission to scientific events your name badge should be clearly visible .

Congress ReportThe official congress report of the Symposium 201 “Gut-Liver Interactions: From IBD to NASH” will be published in English in the second half of 2016 by Karger, Switzerland . Orders for this book at a reduced subscription price of EUR 35,- can be placed at the congress office during the congress in Innsbruck .

Hotel AccommodationPlease contact for reservation of hotel rooms the team of “Innsbruck Tourism”Telephone: +43 (0)512 56 2000 213Telefax: +43 (0)512 56 2000 220E-Mail: a .einwaller@innsbruck .info http://www .innsbruck .info/


21

Directions to Congress Innsbruck

Arriving by planeInnsbruck Airport is situated about 5 km from city center / congress venue . http://www .innsbruck-airport .com/en/

Arriving by carA guidance system will take you simply and directly to the Congress Innsbruck . Participants get a price reduction for park ticket (EUR 10,- per day) when parking directly in the underground carpark of Congress Innsbruck . Therefore, please change your park ticket at the porter desk (entrance Congress Innsbruck) .

Arriving by trainThe favorable location of Innsbruck (north-south axis) makes it possible for you to get to Congress Innsbruck easily by train . Innsbruck has excellent Intercity and Eurocity connections with the cities of Zurich, Vienna, Munich and Bolzano . www .oebb .at

Arriving by busYou will find detailed IVB timetables at www .ivb .atBus service H and The Sightseer stop directly outside the Congress Innsbruck entrance on Rennweg .


22

Directions


Program

P 20

1e 1

-2/2

016

/550

Stü

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49 (0) 761/15 14-125Telefax: +49 (0) 761/15 14-359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

Symposium 201


March 11 – 12, 2016Congress Innsbruck Innsbruck, Austria

CME credits 11

Awarded with

116419_Falk_Innsbruck_Symp_201_Prog_UG.indd 1 01.02.16 16:16

Gut-Liver Interactions: From IBD to · PDF fileSerum levels of lectin complement pathway...

Documents

Transcript of Gut-Liver Interactions: From IBD to · PDF fileSerum levels of lectin complement pathway...